EBOS Group (EBO)•HY26•Released 25 February 2026EBOS HY26: headline NPAT up 13% but underlying NPAT down 4.3% and operating...Statutory earnings flatter on a lower tax rate while underlying profit slipped and cash conversion fell from 69% to 15% of EBITDA.Published 21 April 2026Read briefing→
EBOS Group (EBO)•FY25•Released 27 August 2025Statutory NPAT fell 20.8% while underlying EBITDA hit $585m guidanceReported earnings dropped sharply on a 7.0% revenue decline, yet cash conversion jumped to 75% of EBITDA and net debt eased to 1.65x.Published 22 April 2026Read briefing→
EBOS Group (EBO)•HY25•Released 19 February 2025EBOS HY25: statutory NPAT down 18.9% and leverage up to 3.86x as Healthcare...Operating cash flow nearly doubled to NZ$189.8m, but the dividend now absorbs essentially all statutory earnings while net debt/EBITDA drifts higher.Published 22 April 2026Read briefing→
EBOS Group (EBO)•FY24•Released 21 August 2024Revenue +7.8% but operating cash fell 11% and leverage rose to 1.68x EBITDAHeadline earnings grew on a slightly lower tax rate, but cash conversion weakened sharply and gross borrowings jumped 26.3% to fund growth.Published 22 April 2026Read briefing→
EBOS Group (EBO)•HY24•Released 21 February 2024Revenue up 7.1% but PBT flat as cash conversion halved and leverage climbed...Headline growth and a lifted dividend mask a sharp step-down in operating cash flow, a capex surge and net debt to EBITDA rising from 2.9x to 3.6x.Published 22 April 2026Read briefing→